IDEXX Laboratories, Inc. $IDXX Holdings Increased by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 198,562 shares of the company’s stock after acquiring an additional 13,981 shares during the period. Victory Capital Management Inc. owned 0.25% of IDEXX Laboratories worth $126,859,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Empowered Funds LLC boosted its stake in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at $265,000. Arkadios Wealth Advisors acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at $405,000. Bank of Montreal Can boosted its stake in IDEXX Laboratories by 21.1% during the second quarter. Bank of Montreal Can now owns 121,101 shares of the company’s stock valued at $64,951,000 after buying an additional 21,132 shares in the last quarter. Finally, Bridgewater Advisors Inc. acquired a new position in IDEXX Laboratories during the second quarter worth about $249,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 44,199 shares of company stock worth $28,746,535. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 2.1%

IDEXX Laboratories stock opened at $648.70 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The firm has a market capitalization of $51.65 billion, a price-to-earnings ratio of 49.63, a P/E/G ratio of 3.86 and a beta of 1.66. The company has a 50 day moving average price of $669.92 and a 200 day moving average price of $668.75.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the business earned $2.53 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Piper Sandler cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. BTIG Research cut their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Barclays reduced their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. UBS Group decreased their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.